| 구분 |
보고서 (영문) |
| 제약/바이오/임상시험 |
Exelixis's Cabometyx Advances mCRPC Treatment with Big Trial Validation Questions |
| Arexvy’s Potential Label Expansion Will Provide Competitive Advantage in RSV Space |
| Novo Nordisk to Acquire CMO Giant Catalent for $16.5 Billion |
| New Hope for GSK’s Once Potential ADC Blockbuster Blenrep |
| Novo to Buy Catalent: The Backlash Begins |
| PCSK9 Inhibitor Alirocumab Proves Effective in Pediatric Familial Hypercholesterolemia |
| Tozorakimab Flunks Efficacy Endpoint in Phase IIb for DKD |
| 질환별 |
Artificial Intelligence Shows Improved Accuracy of Ovarian Cancer Diagnosis |
| Ovarian Cancer: Opportunity Assessment and Forecast |
| Invasive Meningitis Cases Declined Post Vaccine Rollout in Western Australia |
| Age, Gender and Heart Failure: Understanding the Connection |
| Blood Tests for Alzheimer’s Could Significantly Improve Diagnosis in Patients |
| Premature Labor (PL): Competitive Landscape |
| 컨퍼런스/심포지엄/학회/기타 |
Alternative Therapies Are Needed to Combat the Impending Threat of AMR |
| International Gaucher Alliance Marks 30th Year, Unveils 5-Year Strategic Plan to 2029 |
| Conference Organizing Tool – ECCO 2024 |
